Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Our method is widely applicable across drug classes and modalities. We specifically apply our approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single gene driver mutations or synthetic lethal contexts. Leveraging our unique patient selection platform, Acrivon Therapeutics aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials. Acrivon Therapeutics and its clinical biomarker development group is headquartered in the greater Boston area, with biomarker discovery efforts concentrated in our wholly-owned subsidiary in Lund, Sweden.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $100M
Founded date: 2018
Investors 2
| Date | Name | Website |
| 15.11.2021 | RA Capital... | racap.com |
| - | HBM Partne... | hbmpartner... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.11.2021 | Series B | $100M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Daniel | Geffken | Senior Fin... | linkedin.c... | - | - |
Mentions in press and media 3
| Date | Title | Description | Source |
| 05.03.2024 | Acrivon Therapeutics to Present Data at AACR Annual Meeting ... | - | globenewsw... |
| 11.11.2021 | Acrivon Therapeutics Closes Oversubscribed $100 Million Seri... | Proceeds to support the clinical development of advanced Phase 2 lead asset ACR-368, a potent DNA Da... | marketscre... |
| 11.11.2021 | Acrivon Therapeutics Closes Oversubscribed $100 Million Seri... | Proceeds to support the clinical development of advanced Phase 2 lead asset ACR-368, a potent DNA Da... | globenewsw... |